BiotechTube

FYB206 + Keytruda

Phase 1Active
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Melanoma, Stage II

Conditions

Melanoma, Stage II, Melanoma Stage III

Trial Timeline

Jul 1, 2024 → Jun 30, 2026

NCT ID
NCT06551064

About FYB206 + Keytruda

FYB206 + Keytruda is a phase 1 stage product being developed by Formycon AG for Melanoma, Stage II. The current trial status is active. This product is registered under clinical trial identifier NCT06551064. Target conditions include Melanoma, Stage II, Melanoma Stage III.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06551064Phase 1Active

Competing Products

20 competing products in Melanoma, Stage II

See all competitors
ProductCompanyStageHype Score
Binimetinib Oral TabletBiotrialPhase 1
25
Tasisulam-sodium + PaclitaxelEli LillyPhase 3
77
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
25
PLX3397Daiichi SankyoPre-clinical
23
PLX3397 + PembrolizumabDaiichi SankyoPhase 1/2
41
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
DS-8273a + NivolumabDaiichi SankyoPhase 1
33
PLX3397 + vemurafenibDaiichi SankyoPhase 1
33
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
CP-461Astellas PharmaPhase 2
52
YM155Astellas PharmaPhase 2
52
YM155 + DocetaxelAstellas PharmaPhase 2
52
Denileukin diftitoxEisaiPhase 2
52
E7080EisaiPhase 1
33
lenvatinib + pembrolizumabEisaiPhase 2
52
MORAb-004 (monoclonal antibody)EisaiPhase 2
52
Pembrolizumab + LenvatinibEisaiPhase 2
52
Lenvatinib + Lenvatinib + DacarbazineEisaiPhase 1/2
41
E7386 + Pembrolizumab + LenvatinibEisaiPhase 1/2
41

Other Products from Formycon AG

FYB203 2 mg (0.05 mL of 40 mg/mL)Approved
77
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Approved
77
FYB206 + FYB206 + KeytrudaPhase 3
69